Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.
Benign fibrous histiocytoma of bone (BFHB)
Cancer
Denosumab
Pelvic bone
Transformation
Journal
Skeletal radiology
ISSN: 1432-2161
Titre abrégé: Skeletal Radiol
Pays: Germany
ID NLM: 7701953
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
received:
25
10
2023
accepted:
31
01
2024
revised:
30
01
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
Benign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.
Identifiants
pubmed: 38374215
doi: 10.1007/s00256-024-04610-w
pii: 10.1007/s00256-024-04610-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Stout AP. Tumors of the soft tissues. Armed Forces Institute of Pathology; 1953.
Grohs JG, Nicolakis M, Kainberger F, Lang S, Kotz R. Benign fibrous histiocytoma of bone: a report of ten cases and review of literature. Wien Klin Wochenschr. 2002;114(1–2):56–63.
pubmed: 12407938
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70.
Santini-Araujo E, khalil RK, Bertoni F, Park YK, editors. Tumors and tumor-like lesions of bone. Springer Nature; 2020 May 5.
Bertoni F, Calderoni P, Bacchini P, Sudanese A, Baldini N, Present D, et al. Benign fibrous histiocytoma of bone. J Bone Joint Surg Am. 1986;68(8):1225–30.
doi: 10.2106/00004623-198668080-00012
pubmed: 3021777
Czerniak B. Dorfman and Czerniak’s Bone Tumors E-Book. Elsevier Health Sciences; 2015.
Bielamowicz S, Dauer MS, Chang B, Zimmerman MC. Noncutaneous benign fibrous histiocytoma of the head and neck. Otolaryngology- Head and Neck Surgery. 1995;113(1):140–6.
doi: 10.1016/S0194-59989570159-1
pubmed: 7603710
Tanaka T, Kobayashi T, Iino M. Transformation of benign fibrous histiocytoma into malignant fibrous histiocytoma in the mandible: case report. J Oral Maxillofac Surg. 2011;69(7):e285–90.
doi: 10.1016/j.joms.2011.02.067
pubmed: 21549470
Bali A, Singh MP, Padmavathi KM, Ahmed J. Malignant fibrous histiocytoma - an unusual transformation from benign to malignant. J Cancer Sci Ther. 2010;2(2):53–7.
doi: 10.4172/1948-5956.1000023
Indelicato DJ, Keole SR, Shahlaee AH, Shi W, Morris CG, Gibbs CP, et al. Long-term clinical and functional outcomes after treatment for localized Ewing’s tumor of the lower extremity. Int J Radiat Oncol Biol Phys. 2008;70(2):501–9.
doi: 10.1016/j.ijrobp.2007.06.032
pubmed: 17855013
Anderson WJ, Doyle LA. Updates from the 2020 World Health Organization Classification of Soft Tissue and Bone Tumours. Histopathology. 2021;78(5):644–57.
doi: 10.1111/his.14265
pubmed: 33438273
Lee SE, Lee EH, Park H, Sung JY, Lee HW, Kang SY, et al. The diagnostic utility of the GNAS mutation in patients with fibrous dysplasia: meta-analysis of 168 sporadic cases. Hum Pathol. 2012;43(8):1234–42.
doi: 10.1016/j.humpath.2011.09.012
pubmed: 22245114
Cleven AHG, Höcker S, de Bruijn IB, Szuhai K, Cleton-Jansen AM, Bovée JVMG. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39(11):1576–83.
doi: 10.1097/PAS.0000000000000512
pubmed: 26457357
Wągrodzki M, Tysarowski A, Seliga K, Wojnowska A, Stepaniuk M, Castañeda Wysocka P, et al. Diagnostic utility of genetic and immunohistochemical H3–3A mutation analysis in giant cell tumour of bone. Int J Mol Sci. 2022;23(2):969.
doi: 10.3390/ijms23020969
pubmed: 35055156
pmcid: 8778699
Gutierrez LB, Link TM, Horvai AE, Joseph GB, O’Donnell RJ, Motamedi D. Secondary aneurysmal bone cysts and associated primary lesions: imaging features of 49 cases. Clin Imaging. 2020;62:23–32.
doi: 10.1016/j.clinimag.2020.01.022
pubmed: 32036238
Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8.
doi: 10.1016/S1470-2045(13)70277-8
pubmed: 23867211
Yung D, Asano N, Hirozane T, et al. Malignant transformation of metastatic giant cell tumor of bone in a patient undergoing denosumab treatment: A case report. J Orthop Sci. 2023;28(6):1492–6.
Tovazzi V, Dalla Volta A, Pedersini R, Amoroso V, Berruti A. Excess of second tumors in denosumab-treated patients: a metabolic hypothesis. Future Oncol. 2019;15(20):2319–21.
doi: 10.2217/fon-2019-0170
pubmed: 31237145
Chawla S, Blay JY, Rutkowski P, Cesne AL, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719–29.
doi: 10.1016/S1470-2045(19)30663-1
pubmed: 31704134
Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SPD, Pienkowski A, et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015;22(9):2860–8.
doi: 10.1245/s10434-015-4634-9
pubmed: 26033180
pmcid: 4531146
Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, et al. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. BMC Cancer. 2021;21(1):89.
doi: 10.1186/s12885-020-07739-8
pubmed: 33482769
pmcid: 7824947
Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat. 2019;1(18):1533033819840000.
Käcker C, Marx A, Mössinger K, Svehla F, Schneider U, Hogendoorn PCW, et al. High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. Genes Chromosomes Cancer. 2013;52(1):93–8.
doi: 10.1002/gcc.22009
pubmed: 23012233
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss DE, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;21(12):498.
doi: 10.1038/s41467-020-20603-4